FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...
Town Topics

Subscriptions Now Available For Orchestra’s Next Season

Violinist Simone Porter performs with the Princeton Symphony Orchestra during the 2026-27 season at Richardson Auditorium, ...